Bioventus (FRA:4B8) Total Operating Expense: €291.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4B8 Bioventus Inc FRA:4B8
45 GF Score
Price €11.95
GF Value €6.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bioventus Total Operating Expense?

Bioventus FRA:4B8 -8.78% 45 Total Operating Expense is €291.4 Mil as of Jun. 2026. GuruFocus rates FRA:4B8 with a GF Score™ of 45/100 and a GF Value™ of €6.52 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bioventus's Total Operating Expense for the three months ended in Jun. 2026 was €75.5 Mil. Bioventus's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €291.4 Mil.

Bioventus Total Operating Expense Related Terms

Bioventus Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Bioventus's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventus Total Operating Expense Chart

Bioventus Annual Data
Trend Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 249.27 345.26 299.10 348.96 283.41

Bioventus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.59 70.70 74.35 70.84 75.48
FRA:4B8
45GF Score
Bioventus Inc FRA:4B8
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioventus Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €291.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €291.4 Mil mean?
Bioventus (FRA:4B8) has a Total Operating Expense of €291.4 Mil as of Jun. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Bioventus and its competitors.
Is Bioventus' Total Operating Expense too high?
Bioventus' current Total Operating Expense is €291.4 Mil. Overall, Bioventus has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' Total Operating Expense compare to AVR and SIBN?
Bioventus' Total Operating Expense of €291.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Bioventus and its competitors. Bioventus's current Total Operating Expense is €291.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (FRA:4B8) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.52, compared to a current price of €11.95 — trading 83.3% above its estimated fair value. The current Total Operating Expense is €291.4 Mil. Bioventus' overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Bioventus (FRA:4B8), the current Total Operating Expense is €291.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioventus (FRA:4B8) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventus stock appears to be overvalued. The current stock price of €11.95 is trading 83.3% above its estimated GF Value™ of €6.52. GuruFocus considers Bioventus to be Significantly Overvalued.

Key valuation signals for FRA:4B8:

  • Total Operating Expense: €291.4 Mil
  • GF Value™: €6.52 vs. price of €11.95 (83.3% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the FRA:4B8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventus Business Description

Other Exchanges BVS:USA
Address 4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
45GF Score

Get the complete analysis for FRA:4B8

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.95
Price
€6.52
GF Value